ArticleInternational journal of molecular sciences2024
Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:
Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 30 citations in OpenAlex.
- Bridging the gap:Gut microbes · 2026Review
- Article
- Metabolic dysfunction-associated steatotic liver disease: pathogenesis and novel treatment options.Molecular biomedicine · 2026Review
- The Multifaceted Roles of Gut Microbiota and Their Metabolites in Metabolic Dysfunction-associated Steatotic Liver Disease: A Literature Review.Journal of clinical and translational hepatology · 2026Review
- Metabolic Dysfunction-Associated Steatotic Liver Disease: An Update Narrative Review of the Therapeutic Potential of Combining Probiotics and Metformin.Biomedicines · 2026Review
- Gut-Heart Axis: Microbiome Involvement in Wild-Type Transthyretin Amyloidosis.International journal of molecular sciences · 2026Article
- Dihydromyricetin exerts neuroprotective effects in acute spinal cord injury by inhibiting NLRP3/Caspase-1 inflammasome through gut microbiome modeling.Journal of inflammation (London, England) · 2026Article
- A Novel Strain Bifidobacterium longum subsp. longum HN001 Ameliorates High-Fat Diet-Induced Obesity in Mice Through Microbiome-Associated Short-Chain Fatty Acids.Probiotics and antimicrobial proteins · 2026Article
- Gut Microbial Composition, Oxidative Stress, and Immunity in Metabolic Disease: Toward Personalized Interventions.Antioxidants (Basel, Switzerland) · 2026Review
- Dietary pulse prebiotic fibre intake in a rat obese pregnancy model alters maternal caecal microbiome and protects against steatosis in newly weaned offspring.Journal of nutritional science · 2026Article
- Review
- Role of gut microbiota in the development of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease.World journal of gastroenterology · 2025Review
- Exploring the interplay between metabolic dysfunction-associated fatty liver disease and gut dysbiosis: Pathophysiology, clinical implications, and emerging therapies.World journal of hepatology · 2025Review
- Bacteroides- and Prevotella-enriched gut microbial clusters associate with metabolic risks.Gut pathogens · 2025Article
- Identification of a 10-species microbial signature of inflammatory bowel disease by machine learning and external validation.Cell regeneration (London, England) · 2025Article
- The Association BetweenNutrients · 2025Article
- Clinical study of intelligent tongue diagnosis and oral microbiome for classifying TCM syndromes in MASLD.Chinese medicine · 2025Article
- Gut microbiota differences, metabolite changes, and disease intervention during metabolic - dysfunction - related fatty liver progression.World journal of hepatology · 2025Review
- Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease.Frontiers in nutrition · 2025Article
- Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data.Frontiers in microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is characterized by hepatic fat accumulation by metabolic dysfunction. The rising prevalence of MAFLD, especially among Asians, may be associated with changes in gut microbiota. We investigated gut microbiota characteristics and potential mechanisms leading to MAFLD development according to enterotypes. Case-control studies examining the gut microbiota composition between MAFLD and non-MAFLD participants were searched in public databases until July 2023. Gut microbiota was categorized into two enterotypes by principal component analysis. According to the enterotypes, LEfSe, ALDEx2, XGBoost, and DCiPatho were utilized to identify differential abundances and pathogenic microbes in the gut between the MAFLD and non-MAFLD groups. We analyzed microbial community networks with the SprCC module and predicted microbial functions. In the Prevotella enterotype (ET-P), 98.6% of Asians and 65.1% of Caucasians were associated with MAFLD (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.